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Abstract 
Introduction: The predominance of high-molecular-weight forms of prolactin in plasma is referred to as macroprolactinaemia. Unlike 
monomeric hyperprolactinaemia, no previous study has investigated cardiometabolic risk factors in subjects with elevated macroprolactin 
content.
Material and methods: We studied two age-, weight-, and blood pressure-matched groups of premenopausal women: 11 women with 
macroprolactinaemia and 11 women with prolactin levels within the reference range. The outcomes of interest included: glucose homeo-
stasis markers, plasma lipids, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, 
and 25-hydroxyvitamin D. 
Results: Circulating levels of hsCRP and 2-h postchallenge plasma glucose, as well as the homeostatic model assessment 1 of insulin 
resistance ratio, were higher, while levels of HDL cholesterol and 25-hydroxyvitamin D were lower in women with macroprolactinaemia 
than in women without elevated levels of prolactin. In women with elevated levels of big-big prolactin, values of hsCRP and 25-hydroxyvi-
tamin D correlated with the degree of insulin resistance and, similarly to HDL cholesterol and 2-h postchallenge plasma glucose, with 
macroprolactin content. There were no differences between the study groups in concentrations of fasting glucose, total cholesterol, LDL 
cholesterol, triglycerides, uric acid, fibrinogen, and homocysteine.
Conclusions: The obtained results indicate that young women with macroprolactinaemia seem to be characterised by slightly increased 
cardiometabolic risk. (Endokrynol Pol 2019; 70 (4): 336–341)
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Introduction
Apart from monomeric prolactin, being the most abun-
dant (60–90%) and biologically active form of prolactin, 
this hormone occurs in the circulation in two other 
molecular forms: big-prolactin, consisting of prolactin 
dimers, and big-big prolactin, also referred to as macro-
prolactin. Macroprolactin comprises mainly high-mo-
lecular-mass complexes of 23 kDa prolactin and IgG 
autoantibodies [1–3]. Less frequently occurring forms 
of big-big prolactin include: complexes of prolactin with 
IgA or IgM, highly glycosylated monomeric prolactin, 
as well as covalent or non-covalent aggregates of mono-
meric prolactin [4, 5]. Macroprolactinaemia, a condition 
associated with markedly increased circulating big-big 
prolactin levels, is usually diagnosed if more than 60% 
of total prolactin is precipitated by polyethylene glycol 
[5]. The overall prevalence of elevated macroprolactin 
content in the general population ranges between 
3% and 4%, but increases up to 35% in patients with 
elevated prolactin levels [3].
Long-term excess of monomeric prolactin is often 
associated with impaired glucose tolerance, hyperinsu-
linaemia, insulin resistance, atherogenic dyslipidaemia, 
subclinical atherosclerosis, endothelial dysfunction, and 
weight gain [6–13]. Dopamine agonists, the drugs of 
choice in the treatment of monomeric hyperprolacti-
naemia, reduced plasma levels of cardiometabolic risk 
factors [14]. Moreover, cardiometabolic effects of ator-
vastatin [15] and fenofibrate [16] depended on the pro-
lactin status of patients, being much less pronounced (or 
even absent) in women with untreated hyperprolacti-
naemia than in women with bromocriptine-treated hy-
perprolactinaemia and drug-naïve women with normal 
prolactin levels. These results suggest that the presence 
of elevated levels of monomeric prolactin eliminates 
the beneficial effect of atorvastatin on plasma levels of 
cardiometabolic risk factors. 
Although macroprolactinaemia is generally re-
garded as a benign condition and most subjects 
remain asymptomatic [2, 4], some authors disagree 
with this point of view. Gibney et al. [17] observed 
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Munich, Germany). Plasma levels of 25-hydroxyvitamin D were 
detected by competitive immunoassay using and a multichannel 
automatic analyser (Roche Cobas e 411, Mannheim, Germany) 
and commercially available Roche Diagnostic kits. High-sensitivity 
C-reactive protein (hsCRP) was measured by immunoassay with 
chemiluminescent detection (Immulite 2000XPi, Siemens Health-
care, Warsaw, Poland). Fibrinogen levels were measured by the 
Clauss technique, using an automated BCS XP analyser (Siemens 
Healthcare, Warsaw, Poland). The homeostatic model assessment 1 
of insulin resistance (HOMA1-IR) was calculated as follows: fasting 
glucose (mg/dL) × fasting insulin (mIU/L)/405.
In order to estimate macroprolactin content, equal volumes (250 
μL) of plasma and 25% cold polyethylene glycol 6000 dissolved in 
phosphate-buffered saline (Sigma, 137 mmol/L sodium chloride, 
10 mmol/L sodium phosphate, pH = 7.4) were mixed in the ratio 
of 1:1 and incubated for 10 min. After vortex mixing for 30 s, the 
suspension was clarified by centrifugation at 3000 rpm for 30 min. 
To calculate prolactin recovery, the following equation was used: 
plasma prolactin after polyethylene glycol precipitation/plasma 
prolactin before polyethylene glycol precipitation × 100. The 
post-polyethylene glycol prolactin concentration was determined 
by multiplying the prolactin result by two in order to correct for 
the dilution with polyethylene glycol. Macroprolactinaemia was 
diagnosed if the prolactin recovery was below 40%.
Owing to the skewed distributions, values for prolactin, hsCRP, 
fibrinogen, 25-hydroxyvitamin D, homocysteine, triglycerides, and 
HOMA1-IR were natural-log transformed to achieve normality 
and homogeneity of variance. Comparisons between the groups 
were performed using Student’s t-test for independent samples. 
Categorical variables were analysed by c2 test. Correlations between 
the measured variables were calculated using Pearson’s r-tests. 
The clinical importance of the result was assessed based on the 
95% confidence interval. Differences were described as statistically 
significant if 95% confidence intervals did not include the null value 
and/or two-tailed p values were less than 0.05.
Results
There were no differences between the study groups 
in terms of age, smoking, body mass index, waist 
circumference, and systolic and diastolic blood 
pressure. Both groups differed in levels of prolactin 
before polyethylene glycol precipitation and macrop-
rolactin content. Compared to women with prolactin 
levels within the reference range, subjects with mac-
roprolactinaemia had higher plasma levels of hsCRP, 
higher 24-h postchallenge plasma levels of glucose, and 
a higher value of HOMA1-IR, as well as lower plasma 
levels of HDL cholesterol and 25-hydroxyvitamin D. 
There were no differences between the study groups 
in concentrations of fasting glucose, uric acid, total 
cholesterol, LDL cholesterol, triglycerides, fibrinogen, 
and homocysteine (Tab. I).
In women with macroprolactinaemia circulating 
levels of hsCRP and 25-hydroxyvitamin D correlated 
with: levels of prolactin before polyethylene glycol 
precipitation, content of macroprolactin, HOMA1-IR, 
as well as with concentrations of HDL cholesterol and 
2-h postchallenge plasma glucose (Tab. II). Moreover, 
levels of prolactin before polyethylene glycol precipi-
tation and content of macroprolactin correlated with 
HOMA1-IR (r = 0.29, p < 0.05 and r = 0.31, p < 0.05, 
that a significant proportion of women with elevated 
content of big-big prolactin developed galactorrhoea, 
oligomenorrhoea/amenorrhoea, and subfertility. In 
turn, Krysiak et al. [18] found that young women with 
isolated macroprolactinaemia were characterised by ab-
normal sexual desire and depressive symptoms. These 
disturbances, less pronounced than in women with 
monomeric hyperprolactinaemia [18], suggest that 
macroprolactinaemia should be taken into consid-
eration in all women with elevated prolactin levels, 
who complain of infertility, menstrual disturbances, 
or hypolipidaemia. To the best of our knowledge, no 
previous study investigated cardiometabolic risk in pa-
tients with macroprolactinaemia. However, Gulcelik et 
al. [19] observed that macroprolactin occurs much more 
frequently in patients with diabetes than in subjects 
without carbohydrate metabolism disturbances, while 
levels of glycated haemoglobin were higher in diabetic 
patients with macroprolactinaemia than in individuals 
with diabetes but without elevated macroprolactin 
content. Therefore, the current study was aimed at 
comparing plasma lipids, glucose homeostasis mark-
ers and circulating levels of uric acid, high-sensitivity 
C-reactive protein (hsCRP), fibrinogen, homocysteine, 
and 25-hydroxyvitamin D, regarded as well-established 
cardiometabolic risk factors [20-26], between young 
women with macroprolactinaemia and their healthy 
counterparts.
Material and methods
The participants of the study (n = 11) were recruited among 
asymptomatic women (20–45 years old) with elevated levels of 
total prolactin. To be admitted to the study, they had to meet the 
following criteria of macroprolactinaemia: (a) total prolactin levels 
above 40 ng/mL found on two different occasions; (b) prolactin 
recovery less than 40%, and (c) post-polyethylene glycol circulat-
ing prolactin levels less than 25 ng/mL. The study also enrolled 
11 age- and weight-matched healthy women with prolactin and 
macroprolactin levels within the reference range. We excluded 
patients with coexisting prolactinomas or other pituitary tumours, 
impaired renal or hepatic function, thyroid disorders, diabetes, 
acute and chronic inflammatory processes, cardiovascular disease, 
pregnant or breastfeeding women, as well as patients treated with 
any drugs. The study was performed in accordance with the 1964 
Helsinki Declaration, and the study protocol was accepted by the 
local Ethics Committee. All women gave written, informed consent 
to participate in the study.
Venous blood samples were drawn from the antecubital vein 
between 8.00 and 9.00 a.m., at least 12 h after the last meal, in 
a quiet, temperature-controlled room (24–25°C), in order to avoid 
circadian fluctuations of the parameters studied. Moreover, glu-
cose levels were measured in samples obtained 2 h after the oral 
ingestion of 75 g of glucose. Fasting and 2-h postchallenge plasma 
glucose, total cholesterol, high-density lipoprotein (HDL) cho-
lesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, 
and uric acid were measured with standard methods using com-
mercial kits (Roche Diagnostics, Basel, Switzerland). Plasma levels 
of prolactin, insulin, and homocysteine were assayed by direct 
chemiluminescence using acridinium ester technology (ADVIA 
Centaur XP Immunoassay System, Siemens Healthcare Diagnostics, 
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respectively), HDL cholesterol (r = –0.31, p < 0.05 and 
r = –0.25, p < 0.05, respectively), and 2-h postchallenge 
plasma glucose (r = 0.26, p < 0.05 and r = 0.32, p < 0.05, 
respectively). In both study groups, there were cor-
relations between HOMA1-IR and 2-h postchallenge 
plasma glucose (women with macroprolactinaemia: 
r = 0.41, p < 0.001; women without macroprolacti-
naemia: r = 0.43, p < 0.001), HDL cholesterol (women 
with macroprolactinaemia: r = –0.35, p < 0.01; women 
without macroprolactinaemia: r=–0.38, p < 0.01) and 
Table I. Comparison between young women with macroprolactinaemia and their counterparts with prolactin levels within 
the reference range
Women 
with macroprolactinaemia Control women
Difference  
[95% CI]
Number of patients 11 11 –
Age [years; mean (SD)] 34 (7) 32 (7) –2 [–8, 4]
Smoking (%) 27 36 –
Body mass index [kg/m2; mean (SD)] 27.1 (4.8) 26.9 (4.6) –0.2 [–4.4, 4.0]
Waist circumference [cm; mean (SD)] 88 (15) 86 (13) –2 [–15, 11]
Systolic blood pressure [mm Hg; mean (SD)] 134 (13) 132 (15) –2 [–14, 10]
Diastolic blood pressure [mm Hg; mean (SD)] 86 (6) 85 (6) –1 [–6, 4]
Prolactin before polyethylene glycol precipitation 
[ng/mL; mean (SD)] 70 (18) 13 (6) –57 [–69, –45]*
Prolactin after polyethylene glycol precipitation  
[ng/mL; mean (SD)] 14 (7) 12 (5) –2 [–7, 3]
Macroprolactin [%, mean (SD)] 80 (10) 7 (5) –73 [–80, –66]*
Total cholesterol [mg/dL; mean (SD)] 219 (29) 217 (32) –2 [–29, 25]
LDL-cholesterol [mg/dL; mean (SD)] 123 (20) 119 (18) –4 [–21, 13]
HDL-cholesterol [mg/dL; mean (SD)] 50 (7) 56 (6) 6 [1, 11]*
Triglycerides [mg/dL; mean (SD)] 208 (48) 185 (39) –23 [–62, 16]
Fasting glucose [mg/dL; mean (SD)] 91 (8) 90 (8) –1 [–8, 6]
2-h postchallenge glucose [mg/dL; mean (SD)] 137 (18) 122 (15) –15 [–29, –1]*
HOMA1-IR [mean (SD)] 2.6 (0.8) 1.8 (0.7) –0.8 [–1.5, –0.1]*
Uric acid [µmol/L; mean (SD)] 367 (76) 344 (69) –23 [–88, 42]
hsCRP [mg/L; mean (SD)] 2.3 (0.8) 1.3 (0.6) –1.0 [–1.6, –0.4]*
Fibrinogen [mg/dL; mean (SD)] 354 (68) 325 (80) –29 [–95, 37]
Homocysteine [µmol/L; mean (SD)] 15 (7) 13 (8) –2 [–9, 5]
25-hydroxyvitamin D [ng/mL; mean (SD)] 25 (7) 32 (8) 7 [1, 13]*
*statistically significant difference between both groups. HDL — high-density lipoprotein; HOMA1-IR — the homeostatic model assessment 1 of insulin resistance 
ratio; hsCRP — high-sensitivity C-reactive protein; LDL — low-density lipoprotein; SD — standard deviation; CI — confidence interval
Table II. Correlations between the assessed variables in young women with macroprolactinaemia
hsCRP Fibrinogen Homocysteine 25-hydroxyvitamin D Uric acid
Prolactin before polyethylene glycol 
precipitation 0.37** 0.16 0.12 –0.37** 0.19
Prolactin after polyethylene glycol 
precipitation 0.22 0.20 0.15 –0.19 0.18
Macroprolactin 0.40*** 0.21 0.10 –0.34** 0.11
HOMA1-IR 0.35** 0.23 0.11 –0.27* 0.13
2-h postchallenge plasma glucose 0.30* 0.17 0.07 –0.30* 0.20
HDL-cholesterol –0.32* –0.17 –0.03 0.26* –0.22
Data represent the correlation coefficients (r values).*p < 0.05, **p < 0.01, ***p < 0.001. HDL — high-density lipoprotein; HOMA1-IR — the homeostatic model 
assessment 1 of insulin resistance ratio; hsCRP — high-sensitivity C-reactive protein
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triglycerides (women with macroprolactinaemia: 
r = 0.38, p < 0.01; women without macroprolactinae-
mia: r = 0.40, p < 0.001) (data not shown). No other 
correlations were found.
Discussion
This study has shown for the first time that the presence 
of macroprolactinaemia in apparently healthy young 
women was associated with abnormal levels of some 
cardiometabolic risk factors: hsCRP, 2-h postchallenge 
glucose, HDL cholesterol, and 25-hydroxyvitamin D, as 
well with an increased value of HOMA1-IR, suggesting 
that macroprolactinaemia may slightly increase the 
risk of development of cardiovascular and metabolic 
disorders. This risk seems to be less prominent than in 
patients with either untreated or treatment-resistant 
monomeric hyperprolactinaemia, who were charac-
terised by abnormally low levels of 25-hydroxyvitamin 
D, as well as increased circulating concentrations of 
insulin-like growth factor-1, free fatty acids, uric acid, 
hsCRP, homocysteine, and fibrinogen [14]. The par-
ticipants of the current study were individuals with 
selectively increased macroprolactin content in whom 
plasma levels of monomeric prolactin within the refer-
ence range. Therefore, the study protocol allowed us 
to eliminate the possibility that the observed changes 
were secondary to true hyperprolactinaemia coexist-
ing with increased production of big-big prolactin. The 
presence of such coexistences was previously described 
by other research teams [27, 28]. Taking into account 
that disturbances in hsCRP, 2-h postchallenge glucose, 
HDL cholesterol, and 25-hydroxyvitamin D contribute 
to the development of atherosclerosis and diabetes, as 
well as their complications [20–22, 26], the obtained 
results may be clinically significant. Our findings, be-
ing in agreement with previous observations [17, 18], 
suggest that elevated levels of big-big prolactin should 
not be considered as a benign condition without patho-
genic relevance.
All markers, the level of which differed between 
patients with macroprolactinaemia and healthy sub-
jects, correlated with plasma levels of prolactin before 
polyethylene glycol precipitation and content of mac-
roprolactin, but not with plasma levels of prolactin 
after polyethylene glycol precipitation. The presence 
of these correlations indicates that this relationship 
does not seem to be accidental, suggesting that abnor-
mal levels of cardiometabolic risk factors are probably 
directly linked to elevated levels of big-big prolactin. 
It is possible that low vitamin D status, reflected in the 
present study by low levels of 25-hydroxyvitamin D, 
may contribute to the pathogenesis of macroprolacti-
naemia. We think so because exogenous preparations 
of vitamin D administered for four months reduced 
big-big prolactin content [29]. 
Circulating levels of hsCRP and vitamin D correlated 
with HOMA1-IR, 2-h postchallenge plasma glucose, 
and HDL cholesterol, being the markers of insulin 
receptor action [20, 21]. Based on the obtained results, 
it may be assumed that low-grade systemic inflamma-
tion and hypovitaminosis D develop as a consequence 
of carbohydrate metabolism abnormalities, or their 
presence may disturb glucose homeostasis. Similar re-
lationships were observed previously in patients with 
monomeric hyperprolactinaemia, the characteristic 
features of which were hyperinsulinaemia, insulin resis-
tance, atherogenic dyslipidaemia, and weight gain [14].
Two different molecular mechanisms may explain 
the obtained results. According to the first explanation 
put forward by other authors [17], high molecular mass 
complexes of big-big prolactin may dissociate in periph-
eral tissues releasing monomeric prolactin. This possibil-
ity is particularly probable in the case of the commonest 
form of macroprolactin, namely complexes consisting 
of monomeric prolactin and low-affinity, high-capacity 
IgG [1, 2]. Disturbances in cardiometabolic risk factors, 
which are less expressed than in subjects with true 
hyperprolactinaemia may result from the fact that only 
a small percentage of macroprolactin dissociates, and 
the excess of monomeric prolactin is less expressed than 
in subjects with monomeric hyperprolactinaemia. In 
line with an alternative explanation, big-big prolactin 
may have a week affinity to prolactin receptors. How-
ever, taking into account the prolonged clearance rate 
[2, 4], macroprolactin may chronically stimulate prolac-
tin receptors, exerting prolactin-like effects at the level 
of different peripheral tissues.
Although milder than in true hyperprolactinae-
mia, cardiometabolic abnormalities in women with 
elevated macroprolactin content may be much more 
difficult to treat. The only agent found to slightly reduce 
macroprolactin content is exogenous vitamin D [29]. 
Unlike elevated levels of monomeric prolactin, which 
are easy to treat with dopamine agonists, particularly 
with cabergoline [14], the reduction in big-big prolac-
tin content was observed only in some subjects with 
macroprolactinaemia [5, 30]. Moreover, testosterone 
[31] and metformin [32] did not affect macroprolac-
tin levels (although metformin was found to reduce 
concentrations of monomeric prolactin [33, 34]), while 
ethinyl estradiol plus levonorgestrel led to an increase 
in its content [35].
We are aware of some limitations of our study. The 
most important of them is a small number of partici-
pants. Secondly, the study did not investigate clinical 
outcomes, particularly morbidity or mortality. More-
over, because the study included only women, it is not 
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certain whether cardiometabolic risk is increased in 
men with macroprolactinaemia. Finally, the study pro-
tocol does not allow us to conclude whether elevated 
macroprolactin content increases cardiometabolic risk 
in patients with coexistent cardiovascular or metabolic 
disorders. 
Conclusions
Compared to healthy counterparts with plasma pro-
lactin levels within the reference range, women with 
macroprolactinaemia had increased plasma levels of 
hsCRP and 2-h postload glucose, an increased value of 
HOMA1-IR, as well as reduced plasma levels of HDL 
cholesterol and 25-hydroxyvitamin D. Macroprolacti-
naemia-induced changes in hsCRP and 25-hydroxyvi-
tamin D that are correlated with the degree of insulin 
resistance and, similarly to HDL cholesterol and 2-h 
postchallenge plasma glucose, with macroprolactin con-
tent. The obtained results indicate that young women 
with macroprolactinaemia may be characterised by 
slightly increased cardiometabolic risk.
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